Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre

Abstract

In real life, BIC/FTC/TAF showed high rates of virological suppression and also in PLWH carrying lamivudine/emtricitabine resistance substitutions. The tolerability and safety of BIC/FTC/TAF were good, with high persistence observed for patients on this regimen at M6.